Profiling of the drug resistance of thousands of Src tyrosine kinase mutants uncovers a regulatory network that couples autoinhibition to the dynamics of the catalytic domain

Despite the cataloguing of numerous resistance mutations with

[1]  P. Jänne,et al.  Kinase drug discovery 20 years after imatinib: progress and future directions , 2021, Nature Reviews Drug Discovery.

[2]  Dustin J Maly,et al.  Parallel Chemoselective Profiling for Mapping Protein Structure. , 2020, Cell chemical biology.

[3]  Dustin J Maly,et al.  How ATP-competitive inhibitors allosterically modulate tyrosine kinases that contain a Src-like regulatory architecture. , 2020, ACS chemical biology.

[4]  T. Mikkelsen,et al.  Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases , 2020, Nature Structural & Molecular Biology.

[5]  M. Soellner,et al.  Selective Proteolysis to Study the Global Conformation and Regulatory Mechanisms of c-Src Kinase. , 2019, ACS chemical biology.

[6]  B. Turk.  Faculty Opinions recommendation of A Combined Approach Reveals a Regulatory Mechanism Coupling Src's Kinase Activity, Localization, and Phosphotransferase-Independent Functions. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[7]  Alan F. Rubin,et al.  A Combined Approach Reveals a Regulatory Mechanism Coupling Src's Kinase Activity, Localization, and Phosphotransferase-Independent Functions. , 2019, Molecular cell.

[8]  Joshua A. Kritzer,et al.  Yeast can accommodate phosphotyrosine: v-Src toxicity in yeast arises from a single disrupted pathway , 2018, FEMS yeast research.

[9]  Y. Hamuro,et al.  Optimization of Feasibility Stage for Hydrogen/Deuterium Exchange Mass Spectrometry , 2018, Journal of The American Society for Mass Spectrometry.

[10]  J. García-Nafría,et al.  IVA cloning: A single-tube universal cloning system exploiting bacterial In Vivo Assembly , 2016, Scientific Reports.

[11]  H. Gharwan,et al.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications , 2016, Nature Reviews Clinical Oncology.

[12]  S. Fields,et al.  Deep mutational scanning: a new style of protein science , 2014, Nature Methods.

[13]  Dustin J Maly,et al.  Divergent Modulation of Src-Family Kinase Regulatory Interactions with ATP-Competitive Inhibitors , 2014, ACS chemical biology.

[14]  K. Xiao,et al.  Monitoring protein conformational changes and dynamics using stable-isotope labeling and mass spectrometry , 2014, Nature Protocols.

[15]  A. Shaw,et al.  Molecular Pathways Molecular Pathways : Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies , 2014 .

[16]  Peter R Baker,et al.  MS-Viewer: A Web-based Spectral Viewer for Proteomics Results* , 2014, Molecular & Cellular Proteomics.

[17]  D. Volkin,et al.  Minimizing Carry-Over in an Online Pepsin Digestion System used for the H/D Exchange Mass Spectrometric Analysis of an IgG1 Monoclonal Antibody , 2012, Journal of The American Society for Mass Spectrometry.

[18]  L. Mayne,et al.  Minimizing Back Exchange in the Hydrogen Exchange-Mass Spectrometry Experiment , 2012, Journal of The American Society for Mass Spectrometry.

[19]  Zhongqi Zhang,et al.  Improved protein hydrogen/deuterium exchange mass spectrometry platform with fully automated data processing. , 2012, Analytical chemistry.

[20]  Levi A Garraway,et al.  Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.

[21]  H. Kantarjian,et al.  The rise and fall of gatekeeper mutations? The BCR‐ABL1 T315I paradigm , 2012, Cancer.

[22]  A. Musacchio,et al.  A general framework for inhibitor resistance in protein kinases. , 2011, Chemistry & biology.

[23]  J. R. Engen,et al.  False EX1 signatures caused by sample carryover during HX MS analyses. , 2011, International journal of mass spectrometry.

[24]  Lan V. Zhang,et al.  Knocking out multi-gene redundancies via cycles of sexual assortment and fluorescence selection , 2010, Nature Methods.

[25]  D. Baker,et al.  High Resolution Mapping of Protein Sequence–Function Relationships , 2010, Nature Methods.

[26]  Amanda M. Brock,et al.  Affinity reagents that target a specific inactive form of protein kinases. , 2010, Chemistry & biology.

[27]  Dustin J Maly,et al.  Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. , 2010, ACS chemical biology.

[28]  John Kuriyan,et al.  Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. , 2009, Cancer research.

[29]  Rocco Piazza,et al.  Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Warmuth,et al.  A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. , 2009, Molecular cell.

[31]  John Kuriyan,et al.  Activation of tyrosine kinases by mutation of the gatekeeper threonine , 2008, Nature Structural &Molecular Biology.

[32]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[33]  D. Lawrence,et al.  Self-reporting fluorescent substrates of protein tyrosine kinases. , 2006, Journal of the American Chemical Society.

[34]  J. Andersen,et al.  Expression of Rous sarcoma virus transforming protein pp60v-src in Saccharomyces cerevisiae cells , 1987, Molecular and cellular biology.

[35]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[36]  R. Schiestl,et al.  High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method , 2007, Nature Protocols.